메뉴 건너뛰기




Volumn 10, Issue , 2016, Pages 217-226

Spotlight on ixazomib: Potential in the treatment of multiple myeloma

Author keywords

Biological mechanism; Clinical trials; Oral administration; Proteasome inhibitor

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; IXAZOMIB; LENALIDOMIDE; MELPHALAN; METHOTREXATE; PLACEBO; POMALIDOMIDE; PREDNISONE; TACROLIMUS; THALIDOMIDE; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BORON DERIVATIVE; GLYCINE; PROTEASOME INHIBITOR;

EID: 84955111669     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S93602     Document Type: Review
Times cited : (108)

References (39)
  • 1
    • 84926661080 scopus 로고    scopus 로고
    • Novel therapeutic targets in multiple myeloma
    • Cottini F, Anderson K. Novel therapeutic targets in multiple myeloma. Clin Adv Hematol Oncol. 2015;13(4):236–248.
    • (2015) Clin Adv Hematol Oncol , vol.13 , Issue.4 , pp. 236-248
    • Cottini, F.1    Erson, K.2
  • 2
    • 84949530321 scopus 로고    scopus 로고
    • Immunotherapy for multiple myeloma, past, present, and future: Monoclonal antibodies, vaccines, and cellular therapies
    • Sep 4
    • Karp Leaf R, Cho HJ, Avigan D. Immunotherapy for multiple myeloma, past, present, and future: monoclonal antibodies, vaccines, and cellular therapies. Curr Hematol Malig Rep. Epub 2015 Sep 4.
    • (2015) Curr Hematol Malig Rep. Epub
    • Karp Leaf, R.1    Cho, H.J.2    Avigan, D.3
  • 3
    • 84865585877 scopus 로고    scopus 로고
    • Emerging biological insights and novel treatment strategies in multiple myeloma
    • Gentile M, Recchia AG, Mazzone C, et al. Emerging biological insights and novel treatment strategies in multiple myeloma. Expert Opin Emerg Drugs. 2012;17(3):407–438.
    • (2012) Expert Opin Emerg Drugs , vol.17 , Issue.3 , pp. 407-438
    • Gentile, M.1    Recchia, A.G.2    Mazzone, C.3
  • 4
    • 85003819927 scopus 로고    scopus 로고
    • Multiple myeloma: From front-line to relapsed therapies
    • Moreau P, Touzeau C. Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educ Book. 2015;35:e504–e511.
    • (2015) Am Soc Clin Oncol Educ Book , vol.35 , pp. e504-e511
    • Moreau, P.1    Touzeau, C.2
  • 5
    • 84885210510 scopus 로고    scopus 로고
    • Contemporary drug therapies for multiple myeloma
    • de la Puente P, Azab AK. Contemporary drug therapies for multiple myeloma. Drugs Today (Barc). 2013;49(9):563–573.
    • (2013) Drugs Today (Barc) , vol.49 , Issue.9 , pp. 563-573
    • de la Puente, P.1    Azab, A.K.2
  • 6
    • 84920439285 scopus 로고    scopus 로고
    • Molecularly targeted therapies in multiple myeloma
    • de la Puente P, Muz B, Azab F, et al. Molecularly targeted therapies in multiple myeloma. Leuk Res Treatment. 2014;2014:976567.
    • (2014) Leuk Res Treatment , vol.2014
    • de la Puente, P.1    Muz, B.2    Azab, F.3
  • 7
    • 84939494205 scopus 로고    scopus 로고
    • Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    • Kumar SK, LaPlant B, Roy V, et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 2015;4:e338.
    • (2015) Blood Cancer J , vol.4
    • Kumar, S.K.1    Laplant, B.2    Roy, V.3
  • 8
    • 84907362479 scopus 로고    scopus 로고
    • Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system
    • Dou QP, Zonder JA. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. 2014;14(6):517–536.
    • (2014) Curr Cancer Drug Targets , vol.14 , Issue.6 , pp. 517-536
    • Dou, Q.P.1    Zonder, J.A.2
  • 9
    • 79955461011 scopus 로고    scopus 로고
    • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study
    • Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
    • (2011) Lancet Oncol , vol.12 , Issue.5 , pp. 431-440
    • Moreau, P.1    Pylypenko, H.2    Grosicki, S.3
  • 10
    • 84868096248 scopus 로고    scopus 로고
    • Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma
    • Arnulf B, Pylypenko H, Grosicki S, et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica. 2012;97(12):1925–1928.
    • (2012) Haematologica , vol.97 , Issue.12 , pp. 1925-1928
    • Arnulf, B.1    Pylypenko, H.2    Grosicki, S.3
  • 11
    • 84895738375 scopus 로고    scopus 로고
    • Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma
    • Lok A, Mocquard J, Bourcier J, et al. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma. Haematologica. 2014;99(3):e33–e34.
    • (2014) Haematologica , vol.99 , Issue.3 , pp. e33-e34
    • Lok, A.1    Mocquard, J.2    Bourcier, J.3
  • 12
    • 84925952101 scopus 로고    scopus 로고
    • Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: Subanalysis of patients with renal impairment in the phase III MMY-3021 study
    • Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study. Haematologica. 2015;100(5):e207–e210.
    • (2015) Haematologica , vol.100 , Issue.5 , pp. e207-e210
    • Moreau, P.1    Pylypenko, H.2    Grosicki, S.3
  • 13
    • 84928577857 scopus 로고    scopus 로고
    • Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma
    • Wang L, Wang KF, Chang BY, et al. Once-weekly subcutaneous administration of bortezomib in patients with multiple myeloma. Asian Pac J Cancer Prev. 2015;16(5):2093–2098.
    • (2015) Asian Pac J Cancer Prev , vol.16 , Issue.5 , pp. 2093-2098
    • Wang, L.1    Wang, K.F.2    Chang, B.Y.3
  • 14
    • 84883579486 scopus 로고    scopus 로고
    • Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma
    • Steele JM. Carfilzomib: a new proteasome inhibitor for relapsed or refractory multiple myeloma. J Oncol Pharm Pract. 2013;19(4):348–354.
    • (2013) J Oncol Pharm Pract , vol.19 , Issue.4 , pp. 348-354
    • Steele, J.M.1
  • 15
    • 84899158409 scopus 로고    scopus 로고
    • From bortezomib to other inhibitors of the proteasome and beyond
    • Buac D, Shen M, Schmitt S, et al. From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des. 2013;19(22):4025–4038.
    • (2013) Curr Pharm Des , vol.19 , Issue.22 , pp. 4025-4038
    • Buac, D.1    Shen, M.2    Schmitt, S.3
  • 16
    • 84864704046 scopus 로고    scopus 로고
    • Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib
    • Ao L, Wu Y, Kim D, et al. Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib. Mol Pharm. 2012;9(8):2197–2205.
    • (2012) Mol Pharm , vol.9 , Issue.8 , pp. 2197-2205
    • Ao, L.1    Wu, Y.2    Kim, D.3
  • 17
    • 84922380040 scopus 로고    scopus 로고
    • The role of P-glycoprotein in drug resistance in multiple myeloma
    • Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymphoma. 2015;56(1):26–33.
    • (2015) Leuk Lymphoma , vol.56 , Issue.1 , pp. 26-33
    • Abraham, J.1    Salama, N.N.2    Azab, A.K.3
  • 18
    • 34547505458 scopus 로고    scopus 로고
    • Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors
    • Rumpold H, Salvador C, Wolf AM, et al. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem Biophys Res Commun. 2007;361(2):549–554.
    • (2007) Biochem Biophys Res Commun , vol.361 , Issue.2 , pp. 549-554
    • Rumpold, H.1    Salvador, C.2    Wolf, A.M.3
  • 19
    • 84905962613 scopus 로고    scopus 로고
    • Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
    • Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014;124(7):1038–1046.
    • (2014) Blood , vol.124 , Issue.7 , pp. 1038-1046
    • Richardson, P.G.1    Baz, R.2    Wang, M.3
  • 20
    • 80051691845 scopus 로고    scopus 로고
    • In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells
    • Chauhan D, Tian Z, Zou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–5321.
    • (2011) Clin Cancer Res , vol.17 , Issue.16 , pp. 5311-5321
    • Chauhan, D.1    Tian, Z.2    Zou, B.3
  • 21
    • 84908220530 scopus 로고    scopus 로고
    • An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma
    • Offidani M, Corvatta L, Caraffa P, et al. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. OncoTargets Ther. 2014;7:1793–1800.
    • (2014) Oncotargets Ther , vol.7 , pp. 1793-1800
    • Offidani, M.1    Corvatta, L.2    Caraffa, P.3
  • 22
    • 77950238258 scopus 로고    scopus 로고
    • Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer
    • Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70(5):1970–1980.
    • (2010) Cancer Res , vol.70 , Issue.5 , pp. 1970-1980
    • Kupperman, E.1    Lee, E.C.2    Cao, Y.3
  • 24
    • 0032539702 scopus 로고    scopus 로고
    • Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
    • Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8(4):333–338.
    • (1998) Bioorg Med Chem Lett , vol.8 , Issue.4 , pp. 333-338
    • Adams, J.1    Behnke, M.2    Chen, S.3
  • 25
    • 79959410937 scopus 로고    scopus 로고
    • Aminoboronic acids and esters: From synthetic challenges to the discovery of unique classes of enzyme inhibitors
    • Touchet S, Carreaux F, Carboni B, et al. Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors. Chem Soc Rev. 2011;40(7):3895–3914.
    • (2011) Chem Soc Rev , vol.40 , Issue.7 , pp. 3895-3914
    • Touchet, S.1    Carreaux, F.2    Carboni, B.3
  • 26
    • 84879588288 scopus 로고    scopus 로고
    • From epoxomicin to carfilzomib: Chemistry, biology, and medical outcomes
    • Kim KB, Crews CM. From epoxomicin to carfilzomib: chemistry, biology, and medical outcomes. Nat Prod Rep. 2013;30(5):600–604.
    • (2013) Nat Prod Rep , vol.30 , Issue.5 , pp. 600-604
    • Kim, K.B.1    Crews, C.M.2
  • 27
    • 36148944490 scopus 로고    scopus 로고
    • Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma
    • Kuhn DJ, Chen Q, Voorhees PM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood. 2007;110(9):3281–3290.
    • (2007) Blood , vol.110 , Issue.9 , pp. 3281-3290
    • Kuhn, D.J.1    Chen, Q.2    Voorhees, P.M.3
  • 28
    • 84925230724 scopus 로고    scopus 로고
    • Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: An open-label phase 1/2 study
    • Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol. 2014;15(13):1503–1512.
    • (2014) Lancet Oncol , vol.15 , Issue.13 , pp. 1503-1512
    • Kumar, S.K.1    Berdeja, J.G.2    Niesvizky, R.3
  • 29
    • 84868606462 scopus 로고    scopus 로고
    • Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells
    • Tian Z, Zhao JJ, Tai YT, et al. Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012;120(19):3958–3967.
    • (2012) Blood , vol.120 , Issue.19 , pp. 3958-3967
    • Tian, Z.1    Zhao, J.J.2    Tai, Y.T.3
  • 30
    • 84862506605 scopus 로고    scopus 로고
    • Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features
    • Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119(24):5782–5794.
    • (2012) Blood , vol.119 , Issue.24 , pp. 5782-5794
    • Azab, A.K.1    Hu, J.2    Quang, P.3
  • 31
    • 84929323078 scopus 로고    scopus 로고
    • Targeting the bone marrow microenvironment in multiple myeloma
    • Kawano Y, Moschetta M, Manier S, et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015;263(1):160–172.
    • (2015) Immunol Rev , vol.263 , Issue.1 , pp. 160-172
    • Kawano, Y.1    Moschetta, M.2    Manier, S.3
  • 32
    • 66149150580 scopus 로고    scopus 로고
    • CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
    • Azab AK, Runnels JM, Pitsillides C, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009;113(18):4341–4351.
    • (2009) Blood , vol.113 , Issue.18 , pp. 4341-4351
    • Azab, A.K.1    Runnels, J.M.2    Pitsillides, C.3
  • 33
    • 84907223851 scopus 로고    scopus 로고
    • CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma
    • Azab AK, Sahin I, Moschetta M, et al. CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood. 2014;124(12):1905–1914.
    • (2014) Blood , vol.124 , Issue.12 , pp. 1905-1914
    • Azab, A.K.1    Sahin, I.2    Moschetta, M.3
  • 34
    • 84863116045 scopus 로고    scopus 로고
    • P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment
    • Azab AK, Quang P, Azab F, et al. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood. 2012;119(6):1468–1478.
    • (2012) Blood , vol.119 , Issue.6 , pp. 1468-1478
    • Azab, A.K.1    Quang, P.2    Azab, F.3
  • 35
    • 69249087807 scopus 로고    scopus 로고
    • RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma
    • Azab AK, Azab F, Blotta S, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009;114(3):619–629.
    • (2009) Blood , vol.114 , Issue.3 , pp. 619-629
    • Azab, A.K.1    Azab, F.2    Blotta, S.3
  • 36
    • 84863581473 scopus 로고    scopus 로고
    • Myeloma as a model for the process of metastasis: Implications for therapy
    • Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120(1):20–30.
    • (2012) Blood , vol.120 , Issue.1 , pp. 20-30
    • Ghobrial, I.M.1
  • 37
    • 84920505400 scopus 로고    scopus 로고
    • The osteoblastic niche in the context of multiple myeloma
    • Toscani D, Bolzoni M, Accardi F, et al. The osteoblastic niche in the context of multiple myeloma. Ann N Y Acad Sci. 2015;1335:45–62.
    • (2015) Ann N Y Acad Sci , vol.1335 , pp. 45-62
    • Toscani, D.1    Bolzoni, M.2    Accardi, F.3
  • 38
    • 62549117773 scopus 로고    scopus 로고
    • Pathogenesis of myeloma bone disease
    • Roodman GD. Pathogenesis of myeloma bone disease. Leukemia. 2009;23(3):435–441.
    • (2009) Leukemia , vol.23 , Issue.3 , pp. 435-441
    • Roodman, G.D.1
  • 39
    • 84896511237 scopus 로고    scopus 로고
    • Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease
    • Garcia-Gomez A, Quwaider D, Canavese M, et al. Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. Clin Cancer Res. 2014;20(6):1542–1554.
    • (2014) Clin Cancer Res , vol.20 , Issue.6 , pp. 1542-1554
    • Garcia-Gomez, A.1    Quwaider, D.2    Canavese, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.